Thomas Axelsson appointed Acting CEO of Vitrolife

Thomas Axelsson appointed Acting CEO of Vitrolife

Thomas Axelsson, who has long experience of managing companies within
the medical device field, is taking over responsibility for the
fertility area and the Vitrolife Group, and will be Acting CEO while the
recruitment process is ongoing to find a permanent CEO.

As was announced on October 31, 2011, Magnus Nilsson will, after nine
years as CEO of Vitrolife, in the time ahead focus on managing the
subsidiary Xvivo Perfusion AB. Xvivo, with business in the organ
transplant area, is now in an intensive and exciting phase of
development that requires greater focus, and will be a more independent
unit within the Vitrolife Group.

Thomas Axelsson, born in 1959, has amongst other things been CEO of
Stille and Artema, and is Chairman of the Board of amongst other things
Dipylon Medical AB (formerly CMA Microdialysis AB) and Airsonett AB.
Thomas is also a member of the Board of MedCap AB, listed on First
North.

“I have worked with Thomas on the Board of CMA and have great confidence
in his experience and ability to lead Vitrolife,” says Magnus Nilsson.

“We now have a solution in place that we are very pleased with. Magnus
can concentrate to the full on working with our transplantation area,
while Thomas with his competence and experience of managing medical
device companies will work to drive the fertility area and the Vitrolife
Group forward while we recruit a permanent CEO,” says Patrik
Tigerschiöld, Chairman of the Board.

The work on finding a new permanent Director of the fertility area and
CEO is ongoing.

Gothenburg, November 17, 2011

VITROLIFE AB (publ)

Patrik
Tigerschiöld                                                            
                                        

Chairman of the Board

Queries should be addressed to:

Patrik Tigerschiöld, phone 46 8 614 00 22

Thomas Axelsson, phone 46 31 721 81 48

Magnus Nilsson, phone 46 31 721 80 61

Vitrolife is required to publish the information in this press release
in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. The information was submitted for
publication on November 17, at 8:30 a.m.

This is a translation of the Swedish version of the press release. When
in doubt, the Swedish wording prevails.